Who are Aliskiren 3.125 mini-tablets's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Tekturna, Capozide 25/15, Early sequential nephron blockade, ALIS, Aliskiren Hydrochlorothiazide, Keverprazan 14 days.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/aliskiren-3-125-mini-tablets.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Aliskiren 3.125 mini-tablets — Competitive Intelligence Brief

Aliskiren 3.125 mini-tablets (Aliskiren 3.125 mini-tablets) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Renin inhibitor. Area: Cardiovascular.

phase 1 Renin inhibitor Renin Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Aliskiren 3.125 mini-tablets (Aliskiren 3.125 mini-tablets) — Novartis. Aliskiren is a direct renin inhibitor that blocks the conversion of angiotensinogen to angiotensin I, reducing blood pressure.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Aliskiren 3.125 mini-tablets TARGET	Aliskiren 3.125 mini-tablets	Novartis	phase 1	Renin inhibitor	Renin
Tekturna	ALISKIREN	Lxo Ireland	marketed	Renin Inhibitor	Renin	2007-01-01
Capozide 25/15	CAPTOPRIL	Aarxion Anda Hlding	marketed	Thiazide Diuretic [EPC]	Renin	1981-01-01
Early sequential nephron blockade	Early sequential nephron blockade	University of Parma	marketed	RAAS inhibitor combination strategy	Renin-angiotensin-aldosterone system (multiple targets)
ALIS	ALIS	Lxo Ireland	marketed		Multidrug resistance protein 1, Cytochrome P450 3A4, Renin
Aliskiren Hydrochlorothiazide	Aliskiren Hydrochlorothiazide	Novartis	marketed	Direct renin inhibitor / thiazide diuretic combination	Renin; sodium-chloride cotransporter (NCCT)
Keverprazan 14 days	Keverprazan 14 days	Second Affiliated Hospital, School of Medicine, Zhejiang University	marketed	direct renin inhibitor	renin

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Renin inhibitor class)

Novartis · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Aliskiren 3.125 mini-tablets — Competitive Intelligence Brief. https://druglandscape.com/ci/aliskiren-3-125-mini-tablets. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab